The Global #CarT #Cell #Therapy #Market is expected to be valued at US$ 7.7 Billion by 2028, as analyzed by Coherent Market Insights. Increasing demand for genetically engineered #treatment approach for high success rate in #cancer #treatment along with growing cancer incidence rate are key factors driving demand for CAR T cell therapy products #worldwide.
Key players operating in the global CAR-T cell therapy market include Novartis International AG, Kite Pharma, Inc. (Gilead Sciences, Inc.), Juno Therapeutics (Celgene Corporation), Bluebird Bio, Inc. (Celgene Corporation), Sorrento Therapeutics Inc., Mustang Bio, Inc., Aurora Biopharma Inc., Legend Biotech (Genscript Biotech Corporation), Pfizer, Inc., CARsgen Therapeutics, Ltd., and others.
No comments:
Post a Comment